Mark Martin, Managing Director and leader of Houlihan Lokey’s pharma commercialization practice, recently spoke with MM+M about the numerous factors that are likely to catalyze a significant uptick in pharma commercialization M&A activity in the sector—most notably a continued increase in 2024 and 2025 pharma budget visibility, improving comfort with the macroeconomic landscape and the desire for PE investors to start posting returns from their existing portfolio holdings.
Read the article here.